<DOC>
	<DOCNO>NCT01037166</DOCNO>
	<brief_summary>The objective demonstrate entecavir antiviral activity undetectable HBV DNA measure , Roche AmplicorTM PCR Week 48 , ass safety pharmacokinetic entecavir Japanese patient hepatitis B incomplete response current lamivudine therapy</brief_summary>
	<brief_title>Study Japan Safety And Antiviral Activity Adults With Chronic Hepatitis B Current Lamivudine Therapy</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Documentation chronic hepatitis B infection ALL following : 1 . Positive HBsAg OR , negative IgM core antibody confirmation chronic hepatitis B liver biopsy 2 . Patient receive lamivudine therapy 24 week , patient document YMDD mutation lamivudineresistant mutation lamivudine 3 . Documented HBV Viremia â‰¥ 10*5 : copies/mL ALT range 1.3 10 x ULN Subjects must wellcompensated liver disease ) value</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2010</verification_date>
</DOC>